Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06273540 · ClinicalTrials.gov registry record · Phase 1
Phase1, STP7 Cocaine Drug-Drug Interaction Study
A Phase 1 study of Cocaine Use Disorder, sponsored by Stalicla.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT06273540 is a Phase 1 study of Cocaine Use Disorder that has completed, run by Stalicla. The registered enrollment target is 21 participants, below the 103-participant average among 26 other Cocaine Use Disorder trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06273540, a Phase 1 study of Cocaine Use Disorder, has completed, sponsored by Stalicla.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a double-blind, placebo-controlled, parallel group study to compare the effects of STP7 (mavoglurant) vs placebo control on i.v. cocaine's physiological and subjective effects in non-treatment seeking, cocaine-experienced males or females participants between 18 and 59 years of age. The primary objective of this study is to determine if there are clinically meaningful interactions between oral STP7 (mavoglurant) treatment concurrent with 20 and 40 mg i.v. cocaine infusions by measuring adverse events and cardiovascular responses including heart rate, blood pressure, and electrocardiogram (including corrected QT interval). The secondary objectives are: * To evaluate whether administration of STP7 (mavoglurant) alters the pharmacokinetics of cocaine and/or its major metabolite, benzoylecgonine. * To determine the pharmacokinetic of STP7 (mavoglurant) administered at a dose of 200 mg twice a day. * To evaluate whether STP7 (mavoglurant) treatment alters the subjective effects of cocaine measured by Visual Analog Scales (VAS) and Brief Substance Craving Scale (BSCS).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG STP7 (mavoglurant)
- DRUG Cocaine Hydrochloride
Study Locations (1)
Kansas
- Altasciences Clinical Kansas - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2024-04-15 |
| Est. Completion | 2024-10-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06273540
The ClinicalTrials.gov registry entry for NCT06273540 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 103-participant average among 26 other Cocaine Use Disorder trials with a reported enrollment target (80% lower). The listed sponsor is Stalicla, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cocaine Use Disorder appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06273540 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT06273540 about?
NCT06273540 is a clinical study titled "Phase1, STP7 Cocaine Drug-Drug Interaction Study". This is a double-blind, placebo-controlled, parallel group study to compare the effects of STP7 (mavoglurant) vs placebo control on i.v. cocaine's physiological and subjective effects in non-treatment seeking, cocaine-experienced males or females participants between 18 and 59 years of age. The pri...
What is the current status of trial NCT06273540?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2024-04-15. Estimated completion is 2024-10-07.
What conditions does trial NCT06273540 study?
This clinical trial studies the following conditions: Cocaine Use Disorder.
What interventions are being tested in trial NCT06273540?
The interventions under investigation include: Placebo (DRUG), STP7 (mavoglurant) (DRUG), Cocaine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT06273540?
This trial is sponsored by Stalicla, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06273540 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reinforcing Effects of Cocaine During Phendimetrazine Maintenance
COMPLETED · Phase 1
-
Cocaine Opioid Oxytocin Option - Limited
COMPLETED · Phase 1
-
The Effect of Cognitive Enhancement as a Precursor to Computer Based Training for Cognitive Behavioral Therapy (CBT4CBT)
COMPLETED · Phase 1
-
Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder
COMPLETED · Phase 1
-
SXC-2023 Cocaine Interaction Study
COMPLETED · Phase 1
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.